Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department

Ibutilide is a rapid-acting antiarrhythmic drug with worldwide use for conversion of recent-onset atrial fibrillation. Vernakalant, approved in the EU in 2010, is likewise used intravenously, with proven efficacy and safety compared with placebo and amiodarone in randomized clinical trials. The aim...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Europace (London, England) England), 2017-02, Vol.19 (2), p.233-240
Hauptverfasser:	Simon, Alexander, Niederdoeckl, Jan, Skyllouriotis, Ekaterini, Schuetz, Nikola, Herkner, Harald, Weiser, Christoph, Laggner, Anton N, Domanovits, Hans, Spiel, Alexander O
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Anisoles - therapeutic use Anti-Arrhythmia Agents - therapeutic use Atrial Fibrillation - drug therapy Clinical Research Emergency Service, Hospital Female Humans Male Middle Aged Pyrrolidines - therapeutic use Sulfonamides - therapeutic use Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!